Cite
HARVARD Citation
Cheng, Y. et al. (n.d.). 77P A study to evaluate the safety, tolerability and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). Immuno-oncology technology. p. . [Online].